Blood: Pre-treatment of genus Hodgkin's lymphoma for more than 20 years

Nodule lymphoblastation is a rare histological variant of Hodgkin's lymphoma (NLPHL), and the best treatment for Phase I-II NLPHL is uncertainBinkley et alconducted a multi-centered retrospective study that included patients with NLPHL who were diagnosed between 1995 and 2018 as 16-year-old SEBHL, who used a variety of treatments, including radiotherapy (RT), combined modal therapy (CMT-RT-chemotherapy), chemotherapy (CT), post-excision observation, rectumandion and RT, and rituitism monotherapy (R)The evaluation indicators are Progressless Survival (PFS), Pre-Transplant Time, and Overall Survival Rate (OS)559 patients were included in the study, with the median age of 39, 72.3% male and 54.9% in stage IMedian follow-up 5.5 years (range: 3.1-10.1)The five-year PFS and OS of the entire queue were 87.1% and 98.3%, respectivelyInitial treatment with RT, CMT, CT, observation, rituximab, RT or rituximab monotherapy patients had 257 cases (46.0%), 184 cases (32.9%), 47 cases (8.4%), 37 cases (6.6%), 19 (3.4%) and 15 (2.7%)THE FIVE-YEAR PFS AFTER RT, CMT, CT, OBSERVATION, RITUXIXAINE PLUS RT OR RITUXICYT MONOTHERAPY WAS 91.1%, 90.5%, 77.8%, 73.5%, 80.8% AND 38.5%, RESPECTIVELYfor RT queues, the mutated immune architecture pattern and the number of more than two sites are associated with poor PFS, but not in the CMT queueoverall, 21 (3.8%) patients had large cell transformation, and the conversion rate was significantly higher in patients with different immune structure patterns and more than two affected sitesOS in patients with Phase I-II NLPHL performed well after all treatments